Trial Profile
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Corticosteroids
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms INTREPID
- Sponsors GlaxoSmithKline; GSK
- 09 Nov 2022 Results assessing to use linked routine Netherlands healthcare data to assess the validity and practicality of future pragmatic trials using this external database as a method to ascertain healthcare resource utilisation (HCRU) outcomes presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 09 Nov 2022 Results assessing the validity and practicality of future pragmatic trials to ascertain healthcare resource utilisation (HCRU) outcomes by deriving data from INTREPID ,presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 20 May 2020 Primary endpoint, Number of responders based on CAT at Week 24, has been met as per results presented at the 116th International Conference of the American Thoracic Society